Switzerland: ADC Therapeutics enters into new loan agreement to pay off convertible notes

Ameet Mallik, CEO of ADC Therapeutics

NYSE-listed ADC Therapeutics, a commercial-stage biotechnology company, has completed a series of strategic transactions in which it: Entered into a new US$175m senior secured term loan with funds of Owl Rock, a division of Blue Owl Capital, and funds managed by Oaktree Capital Management, with an upfront tranche of US$120m already received; Settled in full…

You must be a HMI Subscriber to view this content.

Subscribe Now »